---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-24-000052"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:29:23.428887+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics enters employment pacts with CSO Jewell ($420K) and CTO Kurtoglu ($440K)

## Summary
- Christopher Jewell appointed CSO; annual base salary $420,000, target bonus 40%.
- Metin Kurtoglu appointed CTO (was COO); annual base salary $440,000, target bonus 40%.
- Severance: 12 months base pay, prorated bonus, and COBRA if terminated without cause or for good reason.
- Change-in-control provision: accelerated vesting of time-based equity awards if termination occurs near a change.
- Both executives subject to 12-18 month non-compete, non-solicit, and confidentiality covenants.

## SEC filing metadata
- accession: 0001453687-24-000052
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000052/0001453687-24-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000052/rnac-20240326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-24-000052
- JSON: https://secwatch.observer/filing/0001453687-24-000052.json
- Plain text: https://secwatch.observer/filing/0001453687-24-000052.txt

## Key facts
- Executive change
  Christopher Jewell was appointed as Chief Scientific Officer at Cartesian Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Scientific Officer
  source text: As previously announced, on November 13, 2023, Cartesian Therapeutics, Inc. (the “Company”) appointed Christopher Jewell, Ph.D., age 43, to serve as the Company’s Chief Scientific Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000052/0001453687-24-000052-index.htm
- Executive change
  Metin Kurtoglu was appointed as Chief Technology Officer at Cartesian Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Technology Officer
  source text: Under the terms of the Kurtoglu Employment Agreement, Dr. Kurtoglu will serve as the Company’s Chief Technology Officer, is entitled to receive an annual base salary of $440,000 and will be eligible for an annual performance bonus targeted at 40% of his annual base salary beginning in 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000052/0001453687-24-000052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.